202:
Philippidis, Alex (1 January 2023). "StockWatch: Illumina
Results Leave Investors, Analysts Anxious: Taysha zooms on $ 150M PIPE financing; Alaunos plunges on job cuts; Design nosedives on patient 'reactions'; Phase IIb trial failure sinks Galecto; Zynerba quadruples on up-to-$ 200M buyout by
87:
Philippidis, Alex (1 January 2023). "StockWatch: Seven
Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts: Gene therapy developer says call for randomized placebo-controlled trial is 'unfeasible'; Evelo falls on clinical miss; HillStream jumps on Dana-Farber deal".
51:
Philippidis, Alex (1 January 2022). "StockWatch: Astellas Hones Gene
Therapy Focus with Taysha Stake: Tricida shares crater after failed Phase III trial; Vaxcyte bolsters challenge to Pfizer with clinical success; ESSA triples after acing prostate cancer study".
166:
Philippidis, Alex (1 January 2023). "Taysha Faces Stock
Delisting, Scraps $ 75M Durham Manufacturing Facility: Company aims to preserve capital while anticipating second-half clinical milestones for key programs, with Q1 results expected Thursday".
123:
Philippidis, Alex (1 October 2020). "Sarepta
Duchenne Muscular Dystrophy Candidate Faces U.S. Food and Drug Administration Assay Request, Patent Suit".
244:
31:
220:
184:
148:
105:
69:
140:
212:
176:
132:
97:
61:
238:
224:
188:
152:
109:
73:
27:
23:
136:
216:
65:
180:
144:
101:
8:
43:
26:developed by Taysha Gene Therapies for
7:
14:
1:
245:Experimental gene therapies
261:
137:10.1089/hum.2020.29137.bfs
16:Experimental gene therapy
217:10.1089/genedge.5.1.106
66:10.1089/genedge.4.1.137
181:10.1089/genedge.5.1.70
102:10.1089/genedge.5.1.28
32:adeno-associated virus
131:(19–20): 1031–1033.
22:is an experimental
125:Human Gene Therapy
252:
229:
228:
199:
193:
192:
163:
157:
156:
120:
114:
113:
84:
78:
77:
48:
30:, delivered via
260:
259:
255:
254:
253:
251:
250:
249:
235:
234:
233:
232:
201:
200:
196:
165:
164:
160:
122:
121:
117:
86:
85:
81:
50:
49:
45:
40:
17:
12:
11:
5:
258:
256:
248:
247:
237:
236:
231:
230:
211:(1): 549–556.
194:
175:(1): 362–367.
158:
115:
96:(1): 128–132.
79:
60:(1): 809–815.
42:
41:
39:
36:
15:
13:
10:
9:
6:
4:
3:
2:
257:
246:
243:
242:
240:
226:
222:
218:
214:
210:
206:
198:
195:
190:
186:
182:
178:
174:
170:
162:
159:
154:
150:
146:
142:
138:
134:
130:
126:
119:
116:
111:
107:
103:
99:
95:
91:
83:
80:
75:
71:
67:
63:
59:
55:
47:
44:
37:
35:
33:
29:
28:Rett syndrome
25:
21:
208:
204:
197:
172:
168:
161:
128:
124:
118:
93:
89:
82:
57:
53:
46:
34:serotype 9.
24:gene therapy
19:
18:
203:Harmony".
38:References
225:265960414
189:258737047
153:224780854
110:257006849
74:253331384
239:Category
205:GEN Edge
169:GEN Edge
145:33074027
90:GEN Edge
54:GEN Edge
20:TSHA-102
223:
187:
151:
143:
108:
72:
221:S2CID
185:S2CID
149:S2CID
106:S2CID
70:S2CID
141:PMID
213:doi
177:doi
133:doi
98:doi
62:doi
241::
219:.
207:.
183:.
171:.
147:.
139:.
129:31
127:.
104:.
92:.
68:.
56:.
227:.
215::
209:5
191:.
179::
173:5
155:.
135::
112:.
100::
94:5
76:.
64::
58:4
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.